Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Anatomic Stage IV Breast Cancer AJCC v8,...
Phase PHASE2
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

This phase II trial studies how well a vaccine, STEMVAC, works in combination with standard endocrine-based therapy (ET) with a CDK4/6 targeted drug therapy, or with the chemotherapy drug capecitabine, in treating patients with hormone receptor (HR)-positive, HER2-negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic). STEMVAC is designed to target proteins that cancer cells use when they become more aggressive and start to spread, and it is believed to work by boosting the immune system to recognize and destroy the invader tumor cells that are causing the disease. Standard ET is treatment that adds, blocks, or removes hormones in order to slow or stop the growth of cancer. Standard CDK4/6 inhibitors, including abemaciclib, may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Capecitabine is in a class of medications called antimetabolites. It is taken up by tumor cells and breaks down into fluorouracil, a substance that kills tumor cells. Giving STEMVAC in combination with standard ET or chemotherapy may be an effective treatment for metastatic HR positive, HER2 negative breast cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine — Given ID
  • Drug: Capecitabine — Given SOC capecitabine
  • Procedure: Computed Tomography — Undergo CT or ultrasound-guided biopsies
  • Drug: Cyclin-Dependent Kinase 4 Inhibitor — Given SOC CDK4/6i
  • Drug: Cyclin-Dependent Kinase 6 Inhibitor — Given SOC CDK4/6i
  • Drug: F-18 16 Alpha-Fluoroestradiol — Undergo FES PET
  • Drug: Hormone Therapy — Given SOC ET
  • Procedure: Positron Emission Tomography — Undergo PET or FES PET

Primary Outcomes

  • Incidence of adverse events (AEs) (Up to 3 years after completion of study treatment)
  • Incidence of immunogenicity (Pre-vaccine up to after 2 booster doses of STEMVAC vaccine (Up to 40 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-11-17
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Washington
Principal Investigators:
  • Natasha Hunter, MD (PRINCIPAL_INVESTIGATOR) - Fred Hutch/University of Washington Cancer Consortium
Contact Information
Study Contact:
Research Coordinator(s)
1-866-932-8588
cvitrial@uw.edu
Research Coordinator(s)
866-932-8588
cvitrial@uw.edu
Fred Hutch/University of Washington Cancer Consortium
Natasha Hunter, MD
Fred Hutch/University of Washington Cancer Consortium
Interventions
  • Biological: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine — Given ID
  • Drug: Capecitabine — Given SOC capecitabine
  • Procedure: Computed Tomography — Undergo CT or ultrasound-guided biopsies
  • Drug: Cyclin-Dependent Kinase 4 Inhibitor — Given SOC CDK4/6i
  • Drug: Cyclin-Dependent Kinase 6 Inhibitor — Given SOC CDK4/6i
Study Locations (1 sites)
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington 98109 United States
Eligibility Criteria
Inclusion Criteria: * Patients must be at least ≥ 18 years of age * Histologically confirmed hormone receptor positive metastatic breast cancer: Tumors that are positive for estrogen receptor (ER) and/or progesterone receptor (PR) * HER2-negative or HER2-low will be included and defined as: * 0-1+ HER2 expression by immunohistochemistry (IHC) OR * Fluorescence in situ hybridization (FISH) negative OR * HER2 2+ and FISH negative * HER2 low per standard of care in breast cancer * Patients should be receiving the following therapies to be eligible for the study: * Cohort 1: First or second line of endocrine therapy in the metastatic setting, in combination with a CDK4/6 inhibitor. Patients must have completed at least 2 cycles of CDK4/6 inhibitor. Patients who have stopped endocrine therapy for intolerance but remain on abemaciclib monotherapy will be considered for enrollment at the PI's discretion * Cohort 2: Progressed on endocrine-based therapies and after completion of at least 1 cycle of capecitabine * Subjects with Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 0 or 1 * Willing to undergo up to two serial biopsies while on study * Have at least 1 site of disease confirmed by the treating oncologist that could be biopsied during treatment * White blood cell (WBC) ≥ 2000/mm\^3 (within 28 days of receiving the study vaccine) * Lymphocyte count ≥ 500/mm\^3 (within 28 days of receiving the study vaccine) * Absolute neutrophil count (ANC) ≥ 800/µL (within 28 days of receiving the study vaccine) * Platelets ≥ 75,000/µL (within 28 days of receiving the study vaccine) * Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN), except patients with Gilbert's syndrome in whom total bilirubin must be ≤ 3.0 mg/dL (within 28 days of receiving the study vaccine) * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 3 x institutional upper limit of normal (ULN) (within 28 days of receiving the study vaccine) * Creatinine ≤ 2.0 mg/dL or creatinine clearance \> 30 mL/min (within 28 days of receiving the study vaccine) * Patients of child-bearing potential must agree to use dual methods of contraception and have a negative urine pregnancy test at screening, and male patients must use an effective barrier method of contraception if sexually active with a female of child-bearing potential. Acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or postmenopausal. Effective methods of contraception must be used throughout the study and until the end of treatment on study * Must have recovered from major infections and/or surgical procedures; and in the opinion of the investigator, not have any significant active concurrent medical illnesses or condition precluding protocol treatment Exclusion Criteria: * Patients with any of the following cardiac conditions: * Symptomatic restrictive cardiomyopathy * Dilated cardiomyopathy * Unstable angina within 4 months prior to enrollment * New York Heart Association functional class III-IV heart failure on active treatment * Symptomatic pericardial effusion * Uncontrolled hypertension * Uncontrolled cardiac arrhythmias * Patients with any autoimmune disease/comorbidity that require chronic steroids or immunosuppressants * A non-breast malignancy requiring radiation or systemic therapy within last 5 years * Known hypersensitivity reaction to the granulocyte-macrophage colony-stimulating factor (GM-CSF) adjuvant; any known contra-indication to GM-CSF * Pregnant or breast feeding * Known history of human immunodeficiency virus (HIV) infection, hepatitis B (e.g., hepatitis B virus surface antigen \[HBsAg\] reactive), or hepatitis C (e.g., hepatitis C virus \[HCV\] ribonucleic acid \[RNA\] \[qualitative\] is detected) * Major surgery within the 4 weeks prior to initiation of study vaccine * Current use of immunosuppressive agents or systemic corticosteroids. Topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption) are allowed. Patients who have received systemic corticosteroids ≤ 30 days prior to starting study drug will be excluded * Patient is currently enrolled in any other clinical protocol or investigational trial that involves administration of experimental therapy and/or therapeutic devices, or investigational drug * NOTE: Biomarker or tissue collection or any other non-interventional clinical trial enrollment is allowed * Must be 14 days between a non-study vaccine and any STEMVAC vaccination * NOTE: The minimum of 14 days does not apply to the tetanus and diphtheria (Td) vaccine * Any condition that may interfere with the patient's participation in the study per treating oncologist
Conditions HR+/HER2- Breast Cancer
Phase PHASE2
Enrollment 357
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

The neoadjuvant treatment options commonly used for HR+/HER2- breast cancer are mainly anthracycline sequential or combined with paclitaxel chemotherapy regimens. Several clinical studies have confirmed that albumin paclitaxel is more effective than solvent-based paclitaxel, and therefore, albumin paclitaxel in combination with epirubicin has also become a commonly used chemotherapy regimen in clinical practice. The aim of this study was to explore the efficacy and safety of the Serplulimab combined with nab-paclitaxel and epirubicin in the neoadjuvant treatment of HR+/HER2- breast cancer

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Serplulimab — Serplulimab is administered intravenously
  • Drug: Epirubicin — Epirubicin ivgtt
  • Drug: Albumin Paclitaxel — Albumin Paclitaxel ivgtt

Primary Outcomes

  • PCR rate (At the time of surgery)
  • PCR rate in PDL1 positive subgroup (At the time of surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-04-15
Completion: 2030-03-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 357 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Henan Cancer Hospital
Contact Information
Study Contact:
Zhenzhen Liu, Dr.
13603862755
liuzhenzhen73@126.com
Zhenzhen Liu, PHD
13603862755
zlyyliuzhenzhen0800@zzu.edu.cn
Henan cancer hospital
Interventions
  • Drug: Serplulimab — Serplulimab is administered intravenously
  • Drug: Epirubicin — Epirubicin ivgtt
  • Drug: Albumin Paclitaxel — Albumin Paclitaxel ivgtt
Study Locations (1 sites)
Henan cancer hospital, Zhengzhou, Henan 450000 China
Eligibility Criteria
3.1 Inclusion Criteria Patients must meet all of the following criteria to be eligible: Age: ≥18 years old. Clinical-pathological confirmation: cT2-cT4 breast cancer, or cT1c with axillary lymph node metastasis. Histopathologically confirmed HR+/HER2- invasive breast cancer: ER and/or PR positive (IHC nuclear staining ≥1%). HER2-negative (IHC 0 or 1+ without FISH testing, or IHC 2+ with FISH-negative amplification). Ki67 ≥20%. Clinically measurable lesions: Measurable lesions confirmed by ultrasound, mammography, or MRI (optional) within 1 month prior to randomization. Adequate organ and bone marrow function (within 1 month prior to chemotherapy): Absolute neutrophil count (ANC) ≥2.0 × 10\^9/L. Hemoglobin ≥90 g/L. Platelet count ≥100 × 10\^9/L. Total bilirubin \<1.5 × ULN (upper limit of normal). Creatinine \<1.5 × ULN. AST/ALT \<1.5 × ULN. Cardiac function: Left ventricular ejection fraction (LVEF) ≥55% by echocardiography. Reproductive status: Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to randomization. ECOG performance status: ≤1. Informed consent: Signed written informed consent. 3.2 Exclusion Criteria Patients meeting any of the following criteria will be excluded: Evidence of metastatic breast cancer: Chest/abdominal CT and bone scan required at any time from diagnosis to randomization to exclude metastasis. PET/CT may substitute for other imaging modalities. Prior systemic therapy: Chemotherapy, endocrine therapy, targeted therapy, or radiotherapy for the current breast cancer. Second primary malignancy, except: Adequately treated non-melanoma skin cancer. Prior immunotherapy: Treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, or other immune checkpoint inhibitors. Immune-related conditions: Diagnosed immunodeficiency or active autoimmune disease. Severe cardiopulmonary disease: Uncontrolled or clinically significant. Active hepatitis: Hepatitis B or C with detectable viral load. Transplant history: Prior organ or bone marrow transplantation. Pregnancy or lactation: Pregnant or breastfeeding women. Other contraindications: Severe uncontrolled comorbidities deemed by investigators to contraindicate chemotherapy or PD-1 inhibitor therapy.
Conditions Advanced Breast Cancer
Phase NA
Enrollment 86
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

To compare the efficacy and safety of capecitabine and cyclophosphamide (XC) versus physician's choice as maintenance therapy for patients with advanced breast cancer who achieved disease control after salvage treatment.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: XC — Capecitabine (bid po, d1-14) and cyclophosphamide (qd po, d1-d14) every 21 days
  • Drug: TPC — Any physician's choice as maintenance therapy (except for XC regimen)

Primary Outcomes

  • Progression-Free Survival (PFS) (From the date of starting maintenance therapy to the date of first documentation of disease progression or death from any cause (up to approximately 1 year))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-06-01
Completion: 2028-02
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 86 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Wenjin Yin
Principal Investigators:
  • Wenjin Yin, M.D. (PRINCIPAL_INVESTIGATOR) - Renji Hospital,School of Medicine, Shanghai Jiaotong University
Contact Information
Study Contact:
Wenjin Yin, M.D.
86(21)68385569
yinwenjin@renji.com
Wenjin Yin
86(21)68385569
yinwenjin@renji.com
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Interventions
  • Drug: XC — Capecitabine (bid po, d1-14) and cyclophosphamide (qd po, d1-d14) every 21 days
  • Drug: TPC — Any physician's choice as maintenance therapy (except for XC regimen)
Study Locations (1 sites)
Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127 China
Eligibility Criteria
Inclusion Criteria: * Female, age≥18 years old * ECOG≤2 * Pathologically confirmed primary breast cancer, with pathologically or radiologically confirmed recurrent or metastatic lesions * HR+/HER2+ or HR-/HER2+ or HR-/HER2- * At least one measurable lesion or bone-only disease (osteolytic or mixed) according to RECIST v1.1 * Disease control (complete response + partial response + stable disease) after salvage treatment * Expected survival ≥6 months * Adequate organ function Exclusion Criteria: * during pregnancy and lactation * Patients with central nervous system metastasis
Conditions Advanced Solid Tumors
Phase PHASE1, PHASE2
Enrollment 300
Locations 8 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2). The study population in dose escalation (Phase 1) consists of patients with advanced solid tumors refractory to standard of care, or for whom no standard of care exists. After the MTD and/or RP2D for single agent LCB84 is determined, dose escalation cohorts with select tumor types will be enrolled. Combination LCB84 and anti-PD-1 Ab will be evaluated in dose escalation after a minimum of 2 dose levels of single agent LCB84 have established DLT safety, to determine the MTD and/or RP2D of combination LCB84 and anti-PD-1 Ab, and to continue into dose expansion cohorts in select tumor types.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: LCB84 — TROP2-directed human monoclonal antibody (Ab) linked to a monomethyl auristatin E (MMAE) prodrug
  • Drug: Anti-PD-1 monoclonal antibody — anti-PD-1 Ab

Primary Outcomes

  • Safety of LCB84 alone and LCB84 in combination with an anti-PD-1 Ab (Phase 1 and 2) (Up to 48 months)
  • Recommended Phase 2 Dose of LCB84 alone and LCB84 in combination with an anti-PD-1 Ab (Phase 1) (Up to 24 months)
  • Objective Response Rate (Phase 2) (Up to 24 months)
  • Clinical Benefit Rate (Phase 2) (Up to 24 months)
  • Duration of Response (Phase 2) (Up to 24 months)
  • Time to Progression (Phase 2) (Up to 24 months)
  • Progression Free Survival (Phase 2) (Up to 24 months)
  • Overall Survival (Phase 2) (Up to 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2023-10-05
Completion: 2027-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: LigaChem Biosciences, Inc.
Collaborators: AntibodyChem Biosciences, Inc.
Principal Investigators:
  • Rodrigo Ruiz-Soto, MD (STUDY_DIRECTOR) - AntibodyChem Biosciences
Contact Information
Study Contact:
David Browning
+1-615-975-7776
dbrowning@ligachembio.com
Yuan Yuan, MD
Cedars Sinai Medical Center
DFCI External Referral
dfcicctiexternalreferral@dfci.harvard.edu
Dana Farber Cancer Institute
Interventions
  • Drug: LCB84 — TROP2-directed human monoclonal antibody (Ab) linked to a monomethyl auristatin E (MMAE) prodrug
  • Drug: Anti-PD-1 monoclonal antibody — anti-PD-1 Ab
Study Locations (8 sites)
Cedars Sinai Medical Center, Los Angeles, California 90048 United States
Dana Farber Cancer Institute, Boston, Massachusetts 02115 United States
University of Michigan, Ann Arbor, Michigan 48109 United States
Tennessee Oncology, Nashville, Tennessee 37203 United States
Mary Crowley Cancer Research, Dallas, Texas 75230 United States
University of Texas Southwestern Medical Center, Dallas, Texas 75390 United States
MD Anderson Cancer Center, Houston, Texas 77030 United States
Princess Margaret Cancer Centre, Toronto, Ontario M5G 2M9 Canada
Eligibility Criteria
Key Inclusion Criteria: * Phase 1 Dose Escalation: histologically or cytologically confirmed advanced solid tumors refractory to standard of care treatment. * Phase 2 Dose Expansion\*: select histologically or cytologically confirmed advanced solid tumors refractory to standard of care treatment. \*expansion cohort indications to be prioritized based on data from Phase 1 dose escalation. * Prior treatment with TROP2-directed therapy is permitted. * Measurable disease as defined by RECIST v1.1 or RANO-BM. * Willingness to provide archival tumor tissue when available or to undergo pre-treatment biopsy if not available. * Mandatory pre- and on-treatment biopsies for enrichment cohorts in Phase 1 dose escalation and Phase 2 expansion cohorts if deemed medically feasible and safe. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Adequate organ function as defined by: * Absolute neutrophil count (ANC) ≥1.5 x 109/L (1500/µL), without colony-stimulating factor support for the past 14 days * Platelets ≥100.0 x 109/L (100 000/µL) * Hemoglobin ≥9.0 g/dL * Aspartate aminotransferase (AST) ≤2.5 x ULN; alanine aminotransferase (ALT) ≤2.5 x ULN (AST, ALT ≤5 x ULN if liver metastases present) Key Exclusion Criteria: * Active or progressing central nervous system (CNS) metastases or any evidence of leptomeningeal disease. Note: Patients with stable or treated CNS metastases may be eligible if all of the following criteria are met: 1) localized treatment for brain metastases completed at least 4 weeks prior to the first dose of study drug 2) no new or progressive neurologic symptoms and without need for immediate local therapy, steroids or anticonvulsants for symptom control (stable or decreasing steroid dose (a stable dose of ≤4 mg dexamethasone oral or equivalent) is permitted) 3) stable brain metastases for at least 1 month prior to screening (baseline) brain MRI. * Persistent toxicities from previous systemic antineoplastic treatments \>Grade 1, excluding alopecia and vitiligo. * Systemic antineoplastic therapy (including antiestrogen therapy) within 5 half-lives or 4 weeks, whichever is shorter, prior to first dose of the study drug. * Concomitant use of systemic steroids at dose of \>10 mg of prednisone or its equivalent per day (exception for brain metastases, as described in exclusion criteria #1 above).
Conditions Breast Cancer
Phase PHASE3
Enrollment 394
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

This clinical trial aims to evaluate the efficacy and safety of Dexmedetomidine Hydrochloride Nasal Spray for conscious sedation and anxiety relief during breast-conserving surgery. The main questions it aims to answer are: Does Dexmedetomidine Hydrochloride Nasal Spray effectively provide intraoperative sedation and improve postoperative awakening time? What changes in vital signs or postoperative complications do participants experience when using this medication? Researchers will compare Dexmedetomidine Hydrochloride Nasal Spray to a placebo (saline nasal spray) to determine its efficacy in breast-conserving surgery. Participants will: Receive preoperative administration of either Dexmedetomidine Hydrochloride Nasal Spray or the placebo nasal spray; Undergo regular intraoperative and postoperative assessments, including sedation scores, awakening time, and pain scores; Provide satisfaction feedback and be monitored for changes in vital signs and complications.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Induction of anesthesia with dexmedetomidine nasal spray prior to surgery — Induction of anesthesia with dexmedetomidine nasal spray prior to surgery
  • Drug: Induction of anesthesia with placebo spray prior to surgery — Induction of anesthesia with placebo spray prior to surgery

Primary Outcomes

  • Observer's Assessment of Alterness/Sedation and Numerical rating scale (From enrollment to the end of the first postoperative day)
  • Hospital Anxiety and Depression Scale (HADS) (From enrollment to the end of the first postoperative day)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-03-01
Completion: 2026-03-01
Eligibility
Age: 20 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 394 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital
Collaborators: Shanghai Hengrui Pharmaceutical Co., Ltd.
Contact Information
Study Contact:
Yajing Yuan
+86 158 2294 6764
yuanyajing@tjmuch.com
Interventions
  • Drug: Induction of anesthesia with dexmedetomidine nasal spray prior to surgery — Induction of anesthesia with dexmedetomidine nasal spray prior to surgery
  • Drug: Induction of anesthesia with placebo spray prior to surgery — Induction of anesthesia with placebo spray prior to surgery
Study Locations (1 sites)
Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 China
Eligibility Criteria
Inclusion Criteria: * Sign the informed consent for * The patients included in the study were women aged between 20 and 70. * ASA (American Society of Anesthesiologists) I-II. * BMI:18-26 Kg/m ² Exclusion Criteria: * Subjects deemed unsuitable for nasal spray administration by the researchers (such as those with severe rhinitis, nasal deformities, etc.); * Severe bradycardia (HR \< 50 beats/min), history of cardiac conduction block; * History of upper respiratory tract infection; * History of asthma; * History of allergy to DEX or local anesthetics; * Subjects who have taken anti-anxiety medication before the operation; * Subjects with a history of ischemic stroke or transient ischemic attack; * Subjects with poorly controlled blood pressure despite medication; * Subjects with a history of mental illness, cognitive impairment, or epilepsy; * Subjects with a history of pregnancy; * Subjects who have been taking sedatives or analgesics for a long time; * Subjects with a history of liver or kidney function impairment; * Subjects with a history of drug or alcohol abuse; * Other situations that the reviewers consider to be disqualifying based on the registration study, such as potential non-compliance with the clinical protocol.
Conditions Breast Cancer, Breast Reconstruction Aft...
Phase NA
Enrollment 25
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

Primary objective of this trial: To evaluate the clinical performance (aesthetic outcome and quality of life) and safety of a 3D-printed biodegradable biological mesh in post-mastectomy immediate breast reconstruction. The study targets adult women undergoing total mastectomy for breast cancer followed by implant-based reconstruction. It aims to determine the utility of the 3D-printed biodegradable mesh in implant-based breast reconstruction, assess its influence on tissue regeneration, postoperative cosmetic result, and complication profile.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Implantation of a silicone breast prosthesis combined with a 3D-printed biodegradable mesh — Nipple-sparing subcutaneous mastectomy combined with an implant for immediate breast reconstruction will be performed according to standard clinical practice. The choice of incision will be at the surgeon's discretion. Intraoperatively, tissue from behind the nipple will be sent for frozen section histopathological examination. If the margin is positive, the nipple-areolar complex will be resected following safety principles. The 3D-printed biodegradable biological mesh will be used to wrap the silicone implant, which is then placed in the subcutaneous tissue. The wound will be soaked and irrigated with sterile distilled water and normal saline. After achieving thorough hemostasis, a drain will be placed, and the skin will be closed in layers.

Primary Outcomes

  • postoperative cosmetic results and safety (At 1 week, 1 month, 3 months, 6 months, 12 months ,18 months,and 24 months post-surgery,through study completion, an average of 2 year.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-15
Completion: 2028-12-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 25 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Xijing Hospital
Contact Information
Study Contact:
Ju Liang Zhang, Prof.
029-84775271
vascularzhang@163.com
Mei Ling Huang, MD
029-84775271
huangmeiling@126.com
Ju Liang Zhang, MD
029-84775271
vascularzhang@163.com
the First Affiliated Hospital of the Air Force Medical University
Interventions
  • Procedure: Implantation of a silicone breast prosthesis combined with a 3D-printed biodegradable mesh — Nipple-sparing subcutaneous mastectomy combined with an implant for immediate breast reconstruction will be performed according to standard clinical practice. The choice of incision will be at the surgeon's discretion. Intraoperatively, tissue from behind the nipple will be sent for frozen section histopathological examination. If the margin is positive, the nipple-areolar complex will be resected following safety principles. The 3D-printed biodegradable biological mesh will be used to wrap the silicone implant, which is then placed in the subcutaneous tissue. The wound will be soaked and irrigated with sterile distilled water and normal saline. After achieving thorough hemostasis, a drain will be placed, and the skin will be closed in layers.
Study Locations (1 sites)
the First Affiliated Hospital of the Air Force Medical University, Xi'an, Shaanxi 710032 China
Eligibility Criteria
Inclusion Criteria: * Female breast cancer patients aged 18 to 70 years. * Histopathologically confirmed invasive breast cancer, as defined by the latest ASCO/NCCN guidelines. * Unable to undergo breast-conserving surgery or willing to undergo total mastectomy with immediate implant-based breast reconstruction. * ECOG performance status of 0-1. * Voluntary participation in the study and signing of the written informed consent form. Exclusion Criteria: * Age \>70 years. * Metastatic breast cancer (Stage IV) at initial diagnosis. * Multicentric, extensive, diffuse lesions, or inflammatory breast cancer. * Tumor involvement of the nipple-areolar complex. * Breast cancer during pregnancy. * History of other malignancies within the past 5 years, except for cured cervical carcinoma in situ or non-melanoma skin cancer. * Abnormal function of vital organs such as heart, lungs, liver, or kidneys; poorly controlled diabetes, etc., rendering the patient unable to tolerate surgery. * Patients deemed unsuitable for participation by the investigator.
Conditions Breast Neoplasms
Phase NA
Enrollment 94
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

For patients refusing implants for breast reconstruction after cancer surgery, autologous tissue flap reconstruction using the latissimus dorsi muscle is an alternative. Conventional surgery leaves a long incision on the back, affecting aesthetics and quality of life. Minimal access techniques result in a smaller, more concealable scar. While previous studies suggest its safety and effectiveness, most are retrospective. To further validate patient satisfaction and short-term outcomes, a prospective, randomized controlled trial comparing minimal access with conventional surgery is planned. The primary endpoint is Breast Q-satisfaction with back score at 6 months. Secondary outcomes include other Breast Q subscales, surgical metrics, and complications. The study aims to enroll 94 patients in total, providing evidence for surgical decision-making in breast cancer reconstruction.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: minimal access breast reconstruction with a latissimus dorsi muscle flap — minimal access breast reconstruction with a latissimus dorsi muscle flap
  • Device: conventional breast reconstruction with a latissimus dorsi muscle flap — conventional breast reconstruction with a latissimus dorsi muscle flap

Primary Outcomes

  • Breast Q-satisfaction with back (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-03
Completion: 2028-11
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 94 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Contact Information
Study Contact:
Shicheng Su
+8613631304227
sushch@mail.sysu.edu.cn
Shicheng Su, M.D., Ph.D.
+86 13632394954
lnl_trial@126.com
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Erwei Song, M.D., Ph.D.
+86 13719237746
lnl_trial@126.com
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Interventions
  • Device: minimal access breast reconstruction with a latissimus dorsi muscle flap — minimal access breast reconstruction with a latissimus dorsi muscle flap
  • Device: conventional breast reconstruction with a latissimus dorsi muscle flap — conventional breast reconstruction with a latissimus dorsi muscle flap
Study Locations (1 sites)
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510120 China
Eligibility Criteria
Inclusion Criteria: 1. Female patients with early-stage breast cancer between the ages of 18 and 70. 2. Breast cancer was confirmed by histology or biopsy. 3. Breast-conserving surgery or multifocal breast cancer or large unifocal breast cancer (\<5cm) can be accepted. 4. After neoadjuvant therapy, large monofocal carcinoma (\>5 cm) confined to the breast shrunk to \<5 cm. 5. No chest wall, cutaneous or NAC invasion (including Paget's disease). 6. Mild to moderate breast sagging, and the patient has the willingness to undergo autologous reconstruction of the latissimus dorsi. 7. There is no need to obtain additional back skins. 8. Willing to participate and able to complete follow-up and evaluation during the study. Exclusion Criteria: 1. Patients with advanced breast cancer (stage III and above) or metastatic breast cancer or inflammatory breast cancer. 2. The risk of recurrence is expected to be high. 3. History of thoracic and dorsal vascular injury. 4. Patients with severe heart, lung, or liver disease who cannot withstand surgery and anesthesia. 5. Patients with active infection or severe immune system disease. 6. Patients with severe allergic reactions to materials related to latissimus dorsi muscle flap transplantation. 7. Patients with other major surgeries or reconstructive surgeries planned for the near future. 8. Patients with cognitive dysfunction or psychiatric disorders who cannot understand and cooperate with the requirements of the study. 9. Patients who refuse to participate in the study or are unable to complete follow-up and evaluation during the study.
Conditions Breast Cancer, Neoplasm, Breast, Breast ...
Phase PHASE4
Enrollment 600
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

Breast cancer is the most commonly cancer in women in the overall global population. According to the World Cancer Research Fund International, there were more than 2.25 million new cases of breast cancer in women in 2020. Although the modern treatment strategies, based on the complex care, which consists of surgery, radiotherapy, hormone therapy, and targeted chemotherapy directed at specific cancer molecules have substantially reduced the risk of death due to breast cancer, their wide adoption results in the wider prevalence of cardiotoxicity, defined as either symptomatic heart failure, or asymptomatic contractile dysfunction. The occurrence of cardiotoxicity induced by anti-cancer therapies is estimated at 5-15%, and its development is the primary cause of therapy termination, which significantly reduces the probability of the efficacy of treatment. Several attempts have been made to determine the efficacious preventive strategy, which could diminish the risk of cancer-therapy induced cardiotoxicity. The results of the prior studies indicated a trend towards lower risk of troponin elevation, or left ventricular contractile dysfunction with the introduction of drugs interfering with the renin-angiotensin-aldosterone (RAA) axis, which constitute the primary treatment modality in heart failure with reduced ejection fraction (HFrEF). Sacubitril/valsartan, the novel therapeutic agent, has been demonstrated to significantly improve prognosis in patients with HFrEF. Prior retrospective, small, single-center studies have shown that treatment with sacubitril/valsartan may reduce the risk of cancer-therapy induced cardiotoxicity, or reverse contractile dysfunction caused by anti-cancer therapy. However, no large randomized data confirmed these findings. Therefore, the Sacubitril/Valsartan in PriMAry preventIoN of the cardiotoxicity of systematic breaST canceR trEAtMent) study, has been designed to verify, whether the preventive use of sacubitril/valsartan administered in the doses recommended in patients with HFrEF in breast cancer patients undergoing adjuvant chemotherapy with anthracyclines or anthracyclines and HER-2 monoclonal antibodies, will reduce the incidence of cardiotoxicity defined as impaired left ventricular systolic function on transthoracic echocardiography (TTE). In the trial, a total of 480 patients with histologically confirmed breast cancer, who are eligible for chemotherapy with anthracyclines or anthracyclines and HER-2 monoclonal antibodies, will undergo 1:1 randomization to either preventive treatment with sacubitril/valsartan or placebo. The patients will be followed for 24 months, and will have repetitive efficacy and safety examinations, including echocardiography, MRI (optionally), electrocardiography including 24-h Holter monitoring, blood tests, functional capacity tests and quality of life assessment.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Triple

Interventions / Regimen

  • Drug: Sacubitril-valsartan — Sacubitril/valsartan (Entresto®) administered in the target dose of 200 mg b.i.d. (97/103 mg of sacubitril and valsartan respectively) for the period of 24 months. In case of target dose intolerance, the physician-in-charge will be able to reduce the dose to 100 mg b.i.d. (49/51mg of sacubitril and valsartan respectively). Physicians will be strongly encouraged to evaluate the possibility of drug dose uptitration to the target dose of 200 mg b.i.d.
  • Drug: Placebo — Placebo matching the sacubitril/valsartan (Entresto®) administered in the target dose matching the dosing of 200 mg b.i.d. (97/103 mg) for the period of 24 months. In case of intolerance of target dose of placebo, the physician-in-charge will be able to reduce the dose to placebo matching the dose of 100 mg b.i.d. (49/51mg). Physicians will be strongly encouraged to evaluate the possibility of drug dose uptitration to the target dose of placebo matching the dose of 200 mg b.i.d.

Primary Outcomes

  • Change in left ventricular ejection fraction (LVEF) by ≥5% (Within 24 months from the randomization visit)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2024-04-17
Completion: 2029-02
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Silesian Centre for Heart Diseases
Collaborators: Medical Research Agency, Poland
Principal Investigators:
  • Mateusz Tajstra (PRINCIPAL_INVESTIGATOR) - 3rd Department of Cardiology, School of Medical Sciences in Zabrze, Medical University of Silesia, Katowice; Silesian Center for Heart Diseases
Contact Information
Study Contact:
Mateusz Tajstra, MD, PhD, Assoc Prof
+48323733860
mateusztajstra@wp.pl
Lucyna Broja
+48323733853
l.broja@sccs.pl
Barbara Radecka, MD, PhD
+48774416001
brad@onkologia.opole.pl
Regional Cancer Centre in Opole
Interventions
  • Drug: Sacubitril-valsartan — Sacubitril/valsartan (Entresto®) administered in the target dose of 200 mg b.i.d. (97/103 mg of sacubitril and valsartan respectively) for the period of 24 months. In case of target dose intolerance, the physician-in-charge will be able to reduce the dose to 100 mg b.i.d. (49/51mg of sacubitril and valsartan respectively). Physicians will be strongly encouraged to evaluate the possibility of drug dose uptitration to the target dose of 200 mg b.i.d.
  • Drug: Placebo — Placebo matching the sacubitril/valsartan (Entresto®) administered in the target dose matching the dosing of 200 mg b.i.d. (97/103 mg) for the period of 24 months. In case of intolerance of target dose of placebo, the physician-in-charge will be able to reduce the dose to placebo matching the dose of 100 mg b.i.d. (49/51mg). Physicians will be strongly encouraged to evaluate the possibility of drug dose uptitration to the target dose of placebo matching the dose of 200 mg b.i.d.
Study Locations (4 sites)
Regional Cancer Centre in Opole, Opole, Opole Voivodeship 45-061 Poland
Maria Sklodowska-Curie Institute - Oncology Centre (MSCI), Gliwice Branch, Gliwice, Silesian Voivodeship 44102 Poland
Silesian Center for Heart Diseases, Zabrze, Silesian Voivodeship 41800 Poland
Holy Cross Cancer Centre, Cardio-Oncology Division, Kielce, Świętokrzyskie Voivodeship 25-734 Poland
Eligibility Criteria
Inclusion Criteria: * Written informed consent * Female gender, aged 18 years and over * Patients with histologically confirmed breast cancer and complete assessment of tumor phenotype (Estrogen receptor - ER, Progesterone receptor - PR, Human epidermal growth factor receptor 2 - HER2, Kiel - Ki67) * Ability to take oral medication and willingness to adhere to the planned regimen * Tumor grade IA-IIIC or oligometastatic grade IV * Radical treatment plan including surgery * Plan of use of systemic treatment (preoperative, postoperative or combined) with anthracyclines and/or anti-HER2 drugs * Eastern Cooperative Oncology Group (ECOG) 0-2 general status * LVEF ≥ 50% as assessed by echocardiography * Sinus rhythm Exclusion Criteria: * Prior anthracycline-based chemotherapy and/or thoracic radiotherapy (prior to diagnosis of the cancer being the present cause of therapy) * Clinically relevant HF (NYHA II-IV) * Myocardial infarction (MI) within the last \< 3 months * Symptomatic hypotension or systolic blood pressure (SBP) \< 90 mmHg * Significant valvular disease, symptomatic coronary artery disease (CCS\>2), significant atrioventricular (AV) block, symptomatic sinus node dysfunction * Expected survival \<12 months * Glomerular filtration rate (GFR) \<30 ml/min/1.73 m2 (screening visit) * K+\>5.5mmol/L (screening visit) * Contraindications to angiotensin converting enzyme inhibitor (ACE-I)/angiotensin II receptor blocker (ARB) or LCZ696 if not listed among criteria * Active untreated liver disease * Pregnancy * Conditions/circumstances that may lead to non-compliance with medical staff recommendations (e.g. active drug/alcohol dependence, poorly controlled mental illness)
Conditions Triple Negative Breast Cancer, HER2-nega...
Phase PHASE1
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of the study is to find out if an investigational vaccine called Dendritic Cell (DC) vaccine given together with standard of care chemotherapy drugs can help people with Triple Negative and HR low positive breast cancer.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: HER2 - primed Dendritic cells — Dendritic cell will be administered at ultra-sound guided injections. Participants will receive 8 intratumoral injections. These injections will be administered twice per week per week (given 3 days apart). Participants will receive alternating injections (3 days apart) of HER2-primed followed by HER3-primed DCs. Participants will be treated at the following dose levels: Dose level 1: HER2 - primed Dendritic cells dose 10-20 million Dose level 2: HER2 - primed Dendritic cells dose 30-50 million Dose level 3: HER2 - primed Dendritic cells dose 80-100 million
  • Biological: HER3 - primed Dendritic cells — Dendritic cell will be administered at ultra-sound guided injections. Participants will receive 8 intratumoral injections. These injections will be administered twice per week per week (given 3 days apart). Participants will receive alternating injections (3 days apart) of HER2-primed followed by HER3-primed DCs. Participants will be treated at the following dose levels: Dose level 1: HER3 - primed Dendritic cells dose 10-20 million Dose level 2: HER3 - primed Dendritic cells dose 30-50 million Dose level 3: HER3 - primed Dendritic cells dose 80-100 million

Primary Outcomes

  • Maximum Tolerated Dose (MTD) (4 weeks after start of treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2022-08-26
Completion: 2026-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Collaborators: The Shulas' Foundation
Principal Investigators:
  • Ricardo Costa, MD (PRINCIPAL_INVESTIGATOR) - Moffitt Cancer Center
Contact Information
Study Contact:
Ricardo Costa
813-745-5051
Ricardo.Costa@moffitt.org
Shere Wallace-Morrison
813-745-7962
Shere.Wallace-Morrison@moffitt.org
Moffitt Cancer Center
Ricardo Costa, MD, MSc
Moffitt Cancer Center
Interventions
  • Biological: HER2 - primed Dendritic cells — Dendritic cell will be administered at ultra-sound guided injections. Participants will receive 8 intratumoral injections. These injections will be administered twice per week per week (given 3 days apart). Participants will receive alternating injections (3 days apart) of HER2-primed followed by HER3-primed DCs. Participants will be treated at the following dose levels: Dose level 1: HER2 - primed Dendritic cells dose 10-20 million Dose level 2: HER2 - primed Dendritic cells dose 30-50 million Dose level 3: HER2 - primed Dendritic cells dose 80-100 million
  • Biological: HER3 - primed Dendritic cells — Dendritic cell will be administered at ultra-sound guided injections. Participants will receive 8 intratumoral injections. These injections will be administered twice per week per week (given 3 days apart). Participants will receive alternating injections (3 days apart) of HER2-primed followed by HER3-primed DCs. Participants will be treated at the following dose levels: Dose level 1: HER3 - primed Dendritic cells dose 10-20 million Dose level 2: HER3 - primed Dendritic cells dose 30-50 million Dose level 3: HER3 - primed Dendritic cells dose 80-100 million
Study Locations (1 sites)
Moffitt Cancer Center, Tampa, Florida 33612 United States
Eligibility Criteria
Inclusion Criteria: * A diagnosis of HER2-negative breast cancer. * Diagnosis of HR negative or HR low positive tumor. * Clinical stage T1c, nodal stage N1-N2 or stage T2-4, nodal stage N0-N2 breast cancer. * Participant must be medically and surgically appropriate to undergo neoadjuvant chemotherapy regimen followed by standard of care local therapy as determined by their treating physician. * Age ≥18 years. * ECOG performance status 0 or 1. * Patients must have normal organ and marrow function, as defined below, within 14 days of registration: * \*Absolute neutrophil count (ANC) ≥ 1500/μL * \*Platelets ≥ 75 000/μL * \*Total bilirubin ≤ 1.5 x institutional ULN, except patients with Gilbert's syndrome in whom total bilirubin must be \< 3.0 mg/dL * \*AST/ALT ≤ 3 x institutional ULN * \*Creatinine ≤ 1.5 x institutional ULN * Left ventricular ejection fraction above institutional lower limit of normal (by echocardiogram or MUGA scan). * Female patients of childbearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test at screening. Acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or post-menopausal. Effective methods of contraception must be used throughout the study and for 5 months following the last dose. To show that women do not have childbearing potential, postmenopausal women must be amenorrheic for at least 12 months naturally (and not because of/following chemotherapy) or patients must be surgically sterile. * Ability to understand and the willingness to sign a written informed consent agreement prior to study registration. Exclusion Criteria: * Patients who received prior anthracycline-based chemotherapy for the treatment of any cancer. * Patients with inflammatory breast cancer. * Patients must not be receiving any other investigational agents or active antineoplastic therapies. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune-suppressive treatment, including chronic prolonged systemic corticosteroid use (defined as corticosteroid use lasting one month or more). * Female patients who are pregnant or nursing. * No other prior malignancy is allowed, except for the following: a. adequately treated basal-cell or squamous-cell skin cancer, b. in situ cervical cancer, c. or any other cancer from which the patient has been disease free for at least 3 years. * History of testing positive for human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS). * History of positive test for Hepatitis B or Hepatitis C virus indicating acute or chronic infection. * Patients who have received a live attenuated vaccine ≤ 30 days prior to registration. * Unable to comply with the treatment schedule and study procedures for any reason. * Previously treated with breast cancer-directed vaccine therapies in prior 3 months. * Previously treated with any form HER2- or HER3-primed DC1 therapy.
Conditions Breast Carcinoma, Lung Carcinoma
Phase NA
Enrollment 800
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

This clinical trial assesses the use of advocates and supporters of breast and lung cancer screening to increase lung cancer screening rates amongst eligible participants. Imaging-based cancer screening is utilized with variable frequency. Breast cancer screening with mammography has been widely accepted and is commonly used among eligible women. Lung screening with computed tomography scans is poorly used, despite the potential to decrease deaths from lung cancer. There are many reasons lung screening isn't being used when compared to breast screening, such as smoking stigma and fear, along with a lack of awareness of lung screening. By conducting this trial, researchers want to assess the effectiveness of advocates and supporters of breast and lung screening, and to learn about the psychological barriers to cancer screening, identifying those that are unique to lung screening.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Screening Masking/blinding: None

Interventions / Regimen

  • Behavioral: Health Education — Access electronic patient portal with educational material
  • Other: Health Promotion and Education — Receive materials on breast/lung cancer screening
  • Behavioral: Patient Navigation — Interact with a patient navigator
  • Other: Survey Administration — Ancillary studies

Primary Outcomes

  • Increased rates of lung and breast cancer screening adherence (Up to 3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-07-28
Completion: 2029-09-30
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: true
Enrollment: 800 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jonsson Comprehensive Cancer Center
Principal Investigators:
  • Ashley E Prosper (PRINCIPAL_INVESTIGATOR) - UCLA / Jonsson Comprehensive Cancer Center
Contact Information
Study Contact:
Ashley E. Prosper
310-825-0958
APROSPER@MEDNET.UCLA.EDU
UCLA / Jonsson Comprehensive Cancer Center
Ashley E. Prosper
UCLA / Jonsson Comprehensive Cancer Center
Interventions
  • Behavioral: Health Education — Access electronic patient portal with educational material
  • Other: Health Promotion and Education — Receive materials on breast/lung cancer screening
  • Behavioral: Patient Navigation — Interact with a patient navigator
  • Other: Survey Administration — Ancillary studies
Study Locations (1 sites)
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California 90095 United States
Eligibility Criteria
Inclusion Criteria: * Age: * Breast screening \> 40 * Lung screening 50-80 * Male (M) or Female (F) * Current, former, or never smokers * Close family or friend with smoking history (in or out of state) Exclusion Criteria: * Age: * Breast screening \< 40 * Lung screening \< 50 or \> 80 * Persons who had previously received a diagnosis of lung cancer, had hemoptysis, or had an unexplained weight loss of more than 6.8 kg (15 lb) in the preceding year will also be excluded * Persons with an active cancer
Conditions Breast Cancer
Phase NA
Enrollment 600
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

This study is being performed to find out if a new kind of breast imaging (called dedicated breast CT or BCT) can help doctors to see the small structures in breast tissue more clearly. The investigators also want to find out if using the BCT will provide a more accurate diagnosis of breast cancer.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: Dedicated breast CT(BCT) — The breast CT device will take multiple pictures of the subject's uncompressed breast and creates a 3-D image of the breast.

Primary Outcomes

  • Diagnostic accuracy (12 months after completion of accrual)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08-14
Completion: 2029-12
Eligibility
Age: 40 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Arizona
Collaborators: National Cancer Institute (NCI), National Institutes of Health (NIH)
Principal Investigators:
  • Srinivasan Vedantham, PhD (PRINCIPAL_INVESTIGATOR) - University of Arizona
Contact Information
Study Contact:
Michele Galvan, R.T.R.
520-626-2279
mngalvan@arizona.edu
Michele Galvan, R.T.
520-626-2279
mngalvan@arizona.edu
University of Arizona
Srinivasan Vedantham, PhD
University of Arizona
Interventions
  • Diagnostic Test: Dedicated breast CT(BCT) — The breast CT device will take multiple pictures of the subject's uncompressed breast and creates a 3-D image of the breast.
Study Locations (1 sites)
University of Arizona, Tucson, Arizona 85724 United States
Eligibility Criteria
Inclusion criteria: All subjects that are eligible to participate in the study will be women who satisfy all of the inclusion criteria stated below: * who are 40 years of age or older (typical screening age range) * who are undergoing or scheduled for screening or diagnostic imaging, or need a biopsy to investigate an abnormality in the breast. Exclusion criteria: Subjects that present with any of the criteria listed below will be excluded: * Males, * women less than 40 years old, * women unable to self-consent, * prisoners, * pregnant, suspected to be pregnant, or lactating women (self-reported) * women with physical limitations that may prohibit resting prone on the exam table, such as, but not limited to: frozen shoulder, recent heart surgery, pace maker; * women who are unable to tolerate study constraints, frail, or unable to cooperate; * women who weigh more than 440 lbs (200 Kg), which is the weight limit for the patient support table of the BCT system; * women who have received radiation treatments to the thorax for malignant and nonmalignant conditions, such as (but not limited to) treatment for enlarged thymus gland as an infant, irradiation for benign breast conditions, including breast inflammation after giving birth, and treatment for Hodgkin's disease; * women who have participated in a prior breast clinical trial that gave additional radiation dose, such as an additional mammogram; * women who have received large number of diagnostic x-ray examinations for monitoring of disease such as (but not limited to) tuberculosis, and severe scoliosis.
Conditions Breast Cancer
Phase Not Applicable
Enrollment 6032
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective and retrospective study to evaluate the effect of pre-operative therapy on response and survival, and compare the difference in response and survival by pre-operative regimen or by patient's clinicopathological characteristic in early or advanced breast cancer.

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Interventions / Regimen

  • Drug: pre-operative therapy — pre-operative therapy includes pre-operative chemotherapy, radiation, endocrine therapy, target therapy and other anti-tumor therapy

Primary Outcomes

  • Pathologic Complete Response (at surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-11-01
Completion: 2030-11
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 6032 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: RenJi Hospital
Contact Information
Study Contact:
Wenjin Yin
86(21)68385569
yinwenjin@renji.com
Wenjin Yin
86(21)68385569
yinwenjin@renji.com
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Interventions
  • Drug: pre-operative therapy — pre-operative therapy includes pre-operative chemotherapy, radiation, endocrine therapy, target therapy and other anti-tumor therapy
Study Locations (1 sites)
Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127 China
Eligibility Criteria
Inclusion Criteria: * Female, Aged ≥18 years * Histologically confirmed primary breast cancer * Plan to receive pre-operative therapy * Adequate organ function Exclusion Criteria: * History of neurological or psychological disease, including epilepsy or dementia * Not suitable to participate in this study judged by investigators